دورية أكاديمية
Monocyte or white blood cell counts and β microglobulin predict the durable efficacy of daratumumab with lenalidomide
| العنوان: | Monocyte or white blood cell counts and β microglobulin predict the durable efficacy of daratumumab with lenalidomide |
|---|---|
| المؤلفون: | Yutaka Shimazu, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Ryosuke Yamamura, Satoru Kosugi, Yuji Shimura, Tomoki Ito, Shin-ichi Fuchida, Hitoji Uchiyama, Kentaro Fukushima, Satoshi Yoshihara, Hitoshi Hanamoto, Hirokazu Tanaka, Nobuhiko Uoshima, Kensuke Ohta, Hideo Yagi, Hirohiko Shibayama, Yoshiyuki Onda, Yasuhiro Tanaka, Yoko Adachi, Mitsuhiro Matsuda, Masato Iida, Takashi Miyoshi, Toshimitsu Matsui, Ryoichi Takahashi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda |
| المصدر: | Therapeutic Advances in Hematology, Vol 13 (2022) |
| بيانات النشر: | SAGE Publishing, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Diseases of the blood and blood-forming organs |
| مصطلحات موضوعية: | Diseases of the blood and blood-forming organs, RC633-647.5 |
| الوصف: | Background: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. Objectives: We hypothesized that a durable response to daratumumab could be predicted by the balance between the MM tumor burden and host immune status. Design: We conducted a retrospective study using the real-world data in the Kansai Myeloma Forum (KMF) database. Methods: We retrospectively analyzed 324 relapsed/refractory MM patients who were treated with daratumumab in the KMF database. Results: In this study, 196 patients were treated with daratumumab, lenalidomide, and dexamethasone (DLd) regimen and 128 patients were treated with daratumumab, bortezomib, and dexamethasone (DBd) regimen. The median age at treatment, number of prior treatment regimens and time-to-next-treatment (TTNT) were 68, 4 and 8.02 months, respectively. A multivariate analysis showed that the TTNT under the DLd regimen was longer with either higher monocyte counts (analysis 1), higher white blood cell (WBC) counts (analysis 2), lower β 2 microglobulin (B2MG |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2040-6215 20406207 |
| Relation: | https://doaj.org/toc/2040-6215 |
| DOI: | 10.1177/20406207221142487 |
| URL الوصول: | https://doaj.org/article/de0e47159d65497ba083e4d809b5a35a |
| رقم الأكسشن: | edsdoj.0e47159d65497ba083e4d809b5a35a |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20406215 20406207 |
|---|---|
| DOI: | 10.1177/20406207221142487 |